| Year |
Citation |
Score |
| 2024 |
Schoen MW, Montgomery RB, Owens L, Khan S, Sanfilippo KM, Etzioni RB. Survival in Patients With De Novo Metastatic Prostate Cancer. Jama Network Open. 7: e241970. PMID 38470422 DOI: 10.1001/jamanetworkopen.2024.1970 |
0.41 |
|
| 2024 |
Wright JL, Schenk JM, Gulati R, Beatty SJ, VanDoren M, Lin DW, Porter MP, Morrissey C, Dash A, Gore JL, Etzioni R, Plymate SR, Neuhouser ML. The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance. Cancer. PMID 38353455 DOI: 10.1002/cncr.35241 |
0.378 |
|
| 2024 |
Hammarlund N, Holt SK, Basu A, Etzioni R, Morehead D, Lee JR, Wolff EM, Gore JL, Nyame YA. Isolating the Drivers of Racial Inequities in Prostate Cancer Treatment. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 38214587 DOI: 10.1158/1055-9965.EPI-23-0892 |
0.401 |
|
| 2023 |
Gulati R, Nyame YA, Lange JM, Shoag JE, Tsodikov A, Etzioni R. Racial disparities in prostate cancer mortality: a model-based decomposition of contributing factors. Journal of the National Cancer Institute. Monographs. 2023: 212-218. PMID 37947332 DOI: 10.1093/jncimonographs/lgad018 |
0.388 |
|
| 2023 |
Etzioni R, Gulati R, Patriotis C, Rutter C, Zheng Y, Srivastava S, Feng Z. Revisiting the Standard Blueprint for Biomarker Development to Address Emerging Cancer Early Detection Technologies. Journal of the National Cancer Institute. PMID 37941446 DOI: 10.1093/jnci/djad227 |
0.323 |
|
| 2023 |
Wolf AMD, Oeffinger KC, Shih TY, Walter LC, Church TR, Fontham ETH, Elkin EB, Etzioni RD, Guerra CE, Perkins RB, Kondo KK, Kratzer TB, Manassaram-Baptiste D, Dahut WL, Smith RA. Screening for lung cancer: 2023 guideline update from the American Cancer Society. Ca: a Cancer Journal For Clinicians. PMID 37909877 DOI: 10.3322/caac.21811 |
0.318 |
|
| 2023 |
Caruana M, Gulati R, Etzioni R, Barratt A, Armstrong BK, Chiam K, Nair-Shalliker V, Luo Q, Bang A, Grogan P, Smith DP, O'Connell DL, Canfell K. Benefits and harms of prostate specific antigen testing according to Australian guidelines. International Journal of Cancer. PMID 37819139 DOI: 10.1002/ijc.34731 |
0.46 |
|
| 2023 |
Weiss NS, Etzioni R. Screening for Cancer Precursor Lesions: Assessing the Impact on Cancer Incidence in Randomized Trials. Epidemiology (Cambridge, Mass.). 34: 906-908. PMID 37757879 DOI: 10.1097/EDE.0000000000001652 |
0.343 |
|
| 2023 |
Kensler KH, Johnson R, Morley F, Albrair M, Dickerman BA, Gulati R, Holt SK, Iyer HS, Kibel AS, Lee JR, Preston MA, Vassy JL, Wolff EM, Nyame YA, Etzioni R, et al. Prostate Cancer Screening in African American Men: A Review of the Evidence. Journal of the National Cancer Institute. PMID 37713266 DOI: 10.1093/jnci/djad193 |
0.494 |
|
| 2023 |
Lange J, Zhao Y, Gogebakan KC, Olivas-Martinez A, Ryser MD, Gard CC, Etzioni R. Test sensitivity in a prospective cancer screening program: A critique of a common proxy measure. Statistical Methods in Medical Research. 9622802221142529. PMID 37287266 DOI: 10.1177/09622802221142529 |
0.34 |
|
| 2023 |
Owens L, Gogebakan KC, Menon U, Gulati R, Weiss NS, Etzioni R. Short-term Endpoints for Cancer Screening Trials: Does Tumor Subtype Matter? Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 32: 741-743. PMID 37259797 DOI: 10.1158/1055-9965.EPI-22-1307 |
0.359 |
|
| 2023 |
Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. The Journal of Urology. 101097JU000000000000. PMID 37096582 DOI: 10.1097/JU.0000000000003491 |
0.487 |
|
| 2023 |
Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. The Journal of Urology. 101097JU000000000000. PMID 37096575 DOI: 10.1097/JU.0000000000003492 |
0.467 |
|
| 2023 |
Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, et al. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. Journal of the National Comprehensive Cancer Network : Jnccn. 21: 236-246. PMID 36898362 DOI: 10.6004/jnccn.2023.0014 |
0.428 |
|
| 2023 |
Etzioni R, Castle PE. Shopping for New Cancer Screening Tests. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2300240. PMID 36862969 DOI: 10.1200/JCO.23.00240 |
0.338 |
|
| 2023 |
Nyame YA, Holt SK, Etzioni RD, Gore JL. Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer. Cancer. PMID 36776124 DOI: 10.1002/cncr.34681 |
0.363 |
|
| 2023 |
Pinsky P, Lange J, Etzioni R. Estimating stage-specific sensitivity for cancer screening tests. Journal of Medical Screening. 9691413231154801. PMID 36734139 DOI: 10.1177/09691413231154801 |
0.326 |
|
| 2023 |
Devasia TP, Mariotto AB, Nyame YA, Etzioni R. Estimating the Number of Men Living with Metastatic Prostate Cancer in the United States. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 36716178 DOI: 10.1158/1055-9965.EPI-22-1038 |
0.444 |
|
| 2022 |
Heijnsdijk EAM, Gulati R, Lange JM, Tsodikov A, Roberts R, Etzioni R. Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas. Jama Health Forum. 3: e221116. PMID 35977253 DOI: 10.1001/jamahealthforum.2022.1116 |
0.413 |
|
| 2022 |
Patel NA, Sedrakyan A, Bianco F, Etzioni R, Gorin MA, Hsu WC, Mao J, Nguyen PL, Schaeffer E, Shoag J, Vickers A, Hu JC. Corrigendum to definitive and sustained increase in prostate cancer metastases in the United States. Urologic Oncology. 40: 354. PMID 35654645 DOI: 10.1016/j.urolonc.2022.05.008 |
0.394 |
|
| 2022 |
Owens L, Gulati R, Etzioni R. Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multi-Cancer Early Detection Tests. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 35477176 DOI: 10.1158/1055-9965.EPI-22-0024 |
0.38 |
|
| 2022 |
Nyame YA, Cooperberg MR, Cumberbatch MG, Eggener SE, Etzioni R, Gomez SL, Haiman C, Huang F, Lee CT, Litwin MS, Lyratzopoulos G, Mohler JL, Murphy AB, Pettaway C, Powell IJ, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. European Urology. PMID 35367082 DOI: 10.1016/j.eururo.2022.03.007 |
0.394 |
|
| 2021 |
Jiao B, Gulati R, Katki HA, Castle PE, Etzioni R. A Quantitative Framework to Study Potential Benefits and Harms of Multi-cancer Early Detection Testing. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 34548329 DOI: 10.1158/1055-9965.EPI-21-0380 |
0.358 |
|
| 2021 |
Etzioni R, Gulati R, Weiss NS. Multi-Cancer Early Detection: Learning from the past to Meet the Future. Journal of the National Cancer Institute. PMID 34450655 DOI: 10.1093/jnci/djab168 |
0.307 |
|
| 2021 |
Hendrix N, Gulati R, Jiao B, Kader AK, Ryan ST, Etzioni R. Clarifying the Trade-Offs of Risk-Stratified Screening for Prostate Cancer: A Cost-Effectiveness Study. American Journal of Epidemiology. PMID 34023874 DOI: 10.1093/aje/kwab155 |
0.318 |
|
| 2021 |
Gulati R, Carlsson SV, Etzioni R. When to Discuss Prostate Cancer Screening With Average-Risk Men. American Journal of Preventive Medicine. PMID 33966938 DOI: 10.1016/j.amepre.2021.02.024 |
0.454 |
|
| 2021 |
Nyame YA, Gulati R, Heijnsdijk EAM, Tsodikov A, Mariotto AB, Gore JL, Etzioni R. The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. Journal of the National Cancer Institute. PMID 33963850 DOI: 10.1093/jnci/djab072 |
0.46 |
|
| 2021 |
Lange J, Remmers S, Gulati R, Bill-Axelson A, Johansson JE, Kwiatkowski M, Auvinen A, Hugosson J, Hu JC, Roobol MJ, Carlsson SV, Etzioni R. Impact of cancer screening on metastasis: A prostate cancer case study. Journal of Medical Screening. 969141321989738. PMID 33563084 DOI: 10.1177/0969141321989738 |
0.463 |
|
| 2021 |
Aleshin-Guendel S, Lange J, Goodman P, Weiss NS, Etzioni R. A Latent Disease Model to Reduce Detection Bias in Cancer Risk Prediction Studies. Evaluation & the Health Professions. 163278720984203. PMID 33506704 DOI: 10.1177/0163278720984203 |
0.448 |
|
| 2021 |
Nyame YA, Gulati R, Tsodikov A, Gore JL, Etzioni R. Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer. Jnci Cancer Spectrum. 5: pkaa098. PMID 33442662 DOI: 10.1093/jncics/pkaa098 |
0.491 |
|
| 2020 |
Etzioni R, Nyame YA. Prostate Cancer Screening Guidelines for Black Men: Spotlight on an Empty Stage. Journal of the National Cancer Institute. PMID 33146382 DOI: 10.1093/jnci/djaa172 |
0.454 |
|
| 2020 |
Gogebakan KC, Berry EG, Geller AC, Sonmez K, Leachman SA, Etzioni R. Strategizing screening for melanoma in an era of novel treatments: a model-based approach. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 32958498 DOI: 10.1158/1055-9965.Epi-20-0881 |
0.345 |
|
| 2020 |
A'mar T, Beatty JD, Fedorenko C, Markowitz D, Corey T, Lange J, Schwartz SM, Huang B, Chubak J, Etzioni R. Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study. Jmir Cancer. 6: e18143. PMID 32804084 DOI: 10.2196/18143 |
0.315 |
|
| 2020 |
Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, Guerra CE, Oeffinger KC, Shih YT, Walter LC, Kim JJ, Andrews KS, DeSantis CE, Fedewa SA, Manassaram-Baptiste D, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. Ca: a Cancer Journal For Clinicians. PMID 32729638 DOI: 10.3322/Caac.21628 |
0.368 |
|
| 2020 |
Shoag JE, Nyame YA, Gulati R, Etzioni R, Hu JC. Reconsidering the Trade-offs of Prostate Cancer Screening. The New England Journal of Medicine. 382: 2465-2468. PMID 32558473 DOI: 10.1056/Nejmsb2000250 |
0.511 |
|
| 2020 |
Heijnsdijk EAM, Gulati R, Tsodikov A, Lange JM, Mariotto AB, Vickers AJ, Carlsson SV, Etzioni R. Lifetime benefits and harms of PSA-based risk screening for prostate cancer. Journal of the National Cancer Institute. PMID 32067047 DOI: 10.1093/Jnci/Djaa001 |
0.552 |
|
| 2020 |
Shoag* J, Nyame Y, Gulati R, Etzioni R, Hu J. LBA02-08 RECONSIDERING THE TRADEOFFS OF PROSTATE CANCER SCREENING The Journal of Urology. 203: e1117-e1118. DOI: 10.1097/Ju.0000000000000958.08 |
0.566 |
|
| 2019 |
Gulati R, Etzioni R. Re: Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication. The Journal of Urology. 101097JU000000000000. PMID 31845828 DOI: 10.1097/JU.0000000000000703 |
0.414 |
|
| 2019 |
Lange JM, Laviana AA, Penson DF, Lin DW, Bill-Axelson A, Carlsson SV, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni RB. Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer. PMID 31639200 DOI: 10.1002/Cncr.32557 |
0.429 |
|
| 2019 |
Patel NA, Sedrakyan A, Bianco F, Etzioni R, Gorin MA, Hsu WC, Mao J, Nguyen PL, Schaeffer E, Shoag J, Vickers A, Hu JC. Definitive and sustained increase in prostate cancer metastases in the United States. Urologic Oncology. PMID 31522862 DOI: 10.1016/J.Urolonc.2019.08.002 |
0.487 |
|
| 2019 |
Gulati R, Morgan TM, A'mar T, Psutka SP, Tosoian JJ, Etzioni R. Overdiagnosis and lives saved due to reflex testing men with intermediate prostate-specific antigen levels. Journal of the National Cancer Institute. PMID 31225597 DOI: 10.1093/Jnci/Djz127 |
0.49 |
|
| 2019 |
Gulati R, Psutka SP, Etzioni R. Personalized risks of overdiagnosis for screen-detected prostate cancer incorporating patient comorbidities: Estimation and communication. The Journal of Urology. 101097JU000000000000. PMID 31112106 DOI: 10.1097/Ju.0000000000000346 |
0.55 |
|
| 2019 |
Karlsson A, Jauhiainen A, Gulati R, Eklund M, Grönberg H, Etzioni R, Clements M. A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. Plos One. 14: e0211918. PMID 30763406 DOI: 10.1371/Journal.Pone.0211918 |
0.578 |
|
| 2019 |
Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R, Etzioni R, Hyslop T, Lee SJ, Hwang ES. Cancer Outcomes in DCIS Patients Without Locoregional Treatment. Journal of the National Cancer Institute. PMID 30759222 DOI: 10.1093/Jnci/Djy220 |
0.341 |
|
| 2019 |
Patel* N, Sedrakyan A, Bianco F, Etzioni R, Gorin M, Hsu W, Nguyen P, Schaeffer E, Shoag J, Vickers A, Hu JC. PD30-10 DEFINITIVE AND SUSTAINED INCREASE IN PROSTATE CANCER METASTASES IN THE UNITED STATES Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556142.87942.C6 |
0.477 |
|
| 2018 |
Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R. ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS. The Annals of Applied Statistics. 12: 1773-1795. PMID 30627300 DOI: 10.1214/17-Aoas1130 |
0.463 |
|
| 2018 |
Mariotto AB, Zou Z, Zhang F, Howlader N, Kurian AW, Etzioni R. Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 30337342 DOI: 10.1158/1055-9965.Epi-17-1129 |
0.417 |
|
| 2018 |
Ryser MD, Gulati R, Eisenberg MC, Shen Y, Hwang ES, Etzioni RB. Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials. American Journal of Epidemiology. PMID 30325415 DOI: 10.1093/Aje/Kwy214 |
0.361 |
|
| 2018 |
Birnbaum JK, Duggan C, Anderson BO, Etzioni R. Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study. The Lancet. Global Health. 6: e885-e893. PMID 30012269 DOI: 10.1016/S2214-109X(18)30257-2 |
0.604 |
|
| 2018 |
Lim DM, Gulati R, Aleshin-Guendel S, Gawne A, Wingate JT, Cheng HH, Etzioni R, Yu EY. Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. The Prostate. PMID 29987912 DOI: 10.1002/Pros.23666 |
0.493 |
|
| 2018 |
Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, Etzioni R, McKenna MT, Oeffinger KC, Shih YT, Walter LC, Andrews KS, Brawley OW, Brooks D, Fedewa SA, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. Ca: a Cancer Journal For Clinicians. PMID 29846947 DOI: 10.3322/Caac.21457 |
0.424 |
|
| 2018 |
Tsodikov A, Gulati R, Etzioni R. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Annals of Internal Medicine. 168: 608-609. PMID 29677262 DOI: 10.7326/L17-0738 |
0.469 |
|
| 2018 |
Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, et al. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. European Urology. PMID 29433975 DOI: 10.1016/J.Eururo.2018.01.017 |
0.495 |
|
| 2018 |
Shen Y, Dong W, Gulati R, Ryser MD, Etzioni R. Estimating the frequency of indolent breast cancer in screening trials. Statistical Methods in Medical Research. 962280217754232. PMID 29402176 DOI: 10.1177/0962280217754232 |
0.502 |
|
| 2018 |
Kaur D, Ulloa-Pérez E, Gulati R, Etzioni R. Racial disparities in prostate cancer survival in a screened population: Reality versus artifact. Cancer. PMID 29370459 DOI: 10.1002/Cncr.31253 |
0.548 |
|
| 2018 |
Lim DM, Gulati R, Aleshin-Guendel S, Cheng HH, Gawne AM, Wingate JT, Etzioni RD, Yu EY. Proportion of biochemically-recurrent prostate cancer patients with durable undetectable PSA after short-course androgen deprivation therapy. Journal of Clinical Oncology. 36: 207-207. DOI: 10.1200/Jco.2018.36.6_Suppl.207 |
0.369 |
|
| 2018 |
Yu EY, Gulati R, Aleshin-Guendel S, Cheng HH, Gawne AM, Wingate JT, Etzioni RD, Lim DM. Association of undetectable PSA with time to metastasis and survival after short-course androgen deprivation therapy for biochemically-recurrent prostate cancer patients. Journal of Clinical Oncology. 36: e17073-e17073. DOI: 10.1200/Jco.2018.36.15_Suppl.E17073 |
0.414 |
|
| 2017 |
de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, ... ... Etzioni R, et al. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer. PMID 29211316 DOI: 10.1002/Cncr.31178 |
0.556 |
|
| 2017 |
Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Annals of Internal Medicine. PMID 29181514 DOI: 10.7326/M17-0548 |
0.498 |
|
| 2017 |
Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, ... ... Etzioni R, et al. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Annals of Internal Medicine. PMID 28869989 DOI: 10.7326/M16-2586 |
0.574 |
|
| 2017 |
Lange JM, Trock BJ, Gulati R, Etzioni R. A Framework for Treatment Decision Making at Prostate Cancer Recurrence. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X17711913. PMID 28564551 DOI: 10.1177/0272989X17711913 |
0.479 |
|
| 2017 |
Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 28522448 DOI: 10.1158/1055-9965.Epi-16-0889 |
0.37 |
|
| 2017 |
Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R. Is prostate cancer different in black men? Answers from 3 natural history models. Cancer. PMID 28436011 DOI: 10.1002/Cncr.30687 |
0.506 |
|
| 2017 |
Duffy SW, Etzioni R, Sasieni P. Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality. Evidence-Based Medicine. PMID 28228386 DOI: 10.1136/Ebmed-2016-110632 |
0.387 |
|
| 2017 |
Verdial FC, Etzioni R, Duggan C, Anderson BO. Demographic changes in breast cancer incidence, stage at diagnosis and age associated with population-based mammographic screening. Journal of Surgical Oncology. PMID 28194807 DOI: 10.1002/Jso.24579 |
0.422 |
|
| 2016 |
Lee CI, Etzioni R. Missteps in Current Estimates of Cancer Overdiagnosis. Academic Radiology. PMID 27894707 DOI: 10.1016/J.Acra.2016.05.020 |
0.419 |
|
| 2016 |
Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R. Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27742670 DOI: 10.1158/1055-9965.Epi-16-0434 |
0.547 |
|
| 2016 |
Gulati R, Feuer EJ, Etzioni R. Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies. American Journal of Epidemiology. PMID 27358266 DOI: 10.1093/Aje/Kwv342 |
0.477 |
|
| 2016 |
Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Kawachi MH, Kim S, Lange PH, et al. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 509-19. PMID 27160230 DOI: 10.6004/Jnccn.2016.0060 |
0.467 |
|
| 2016 |
Gulati R, Etzioni R. A Matched Cohort Analysis of Prostate Cancer Screening in Younger Men in Sweden. European Urology. PMID 27090976 DOI: 10.1016/J.Eururo.2016.04.006 |
0.502 |
|
| 2016 |
Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. Jama Oncology. PMID 27010943 DOI: 10.1001/Jamaoncol.2015.6275 |
0.507 |
|
| 2016 |
Etzioni R, Gulati R. Recent Trends in PSA Testing and Prostate Cancer Incidence: A Look at Context. Jama Oncology. PMID 27010657 DOI: 10.1001/Jamaoncol.2015.6310 |
0.522 |
|
| 2016 |
Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, DeSarkar N, Higano C, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nature Medicine. PMID 26928463 DOI: 10.1038/Nm.4053 |
0.379 |
|
| 2016 |
Birnbaum J, Gadi VK, Markowitz E, Etzioni R. The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model. Annals of Internal Medicine. PMID 26756332 DOI: 10.7326/M15-0754 |
0.647 |
|
| 2016 |
Etzioni R, Gulati R. Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them. Journal of the National Cancer Institute. 108. PMID 26582245 DOI: 10.1093/Jnci/Djv345 |
0.434 |
|
| 2016 |
Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Kawachi MH, Lange PH, et al. Prostate cancer early detection, version 2.2015: Clinical practice guidelines in oncology Jnccn Journal of the National Comprehensive Cancer Network. 13: 1534-1561. |
0.404 |
|
| 2016 |
Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Kawachi MH, Kim S, Lange PH, et al. Prostate cancer early detection, Version 2.2016: Featured updates to the NCCN guidelines Jnccn Journal of the National Comprehensive Cancer Network. 14: 509-519. |
0.472 |
|
| 2015 |
Wingate JT, Etzioni R, Macdonald DM, Brand TC. Treatment Trends for Stage I Testicular Seminoma in an Equal-Access Medical System. Clinical Genitourinary Cancer. PMID 26794393 DOI: 10.1016/J.Clgc.2015.12.021 |
0.338 |
|
| 2015 |
Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Kawachi MH, Lange PH, et al. Prostate Cancer Early Detection, Version 2.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 1534-61. PMID 26656522 |
0.461 |
|
| 2015 |
Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, Walter LC, Church TR, Flowers CR, LaMonte SJ, Wolf AM, DeSantis C, Lortet-Tieulent J, Andrews K, Manassaram-Baptiste D, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. Jama. 314: 1599-614. PMID 26501536 DOI: 10.1001/jama.2015.12783 |
0.408 |
|
| 2015 |
Birnbaum JK, Ademuyiwa FO, Carlson JJ, Mallinger L, Mason MW, Etzioni R. Comparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and Costs. Medical Decision Making : An International Journal of the Society For Medical Decision Making. PMID 26304062 DOI: 10.1177/0272989X15601998 |
0.631 |
|
| 2015 |
Barrington WE, Schenk JM, Etzioni R, Arnold KB, Neuhouser ML, Thompson IM, Lucia MS, Kristal AR. Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama Oncology. 1: 342-9. PMID 26181184 DOI: 10.1001/Jamaoncol.2015.0513 |
0.426 |
|
| 2015 |
Elmore JG, Etzioni R. Effect of Screening Mammography on Cancer Incidence and Mortality. Jama Internal Medicine. 175: 1490-1. PMID 26147329 DOI: 10.1001/Jamainternmed.2015.3056 |
0.453 |
|
| 2015 |
Loggers ET, Gao H, Gold LS, Kessler L, Etzioni R, Buist DS. Predictors of preoperative MRI for breast cancer: differences by data source. Journal of Comparative Effectiveness Research. 1-12. PMID 25960128 DOI: 10.2217/Cer.15.1 |
0.342 |
|
| 2015 |
Jeldres C, Cullen J, Hurwitz LM, Wolff EM, Levie KE, Odem-Davis K, Johnston RB, Pham KN, Rosner IL, Brand TC, L'Esperance JO, Sterbis JR, Etzioni R, Porter CR. Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy. Cancer. 121: 2465-73. PMID 25845467 DOI: 10.1002/Cncr.29370 |
0.431 |
|
| 2015 |
Barrington WE, Schenk JM, Etzioni R, Arnold KB, Neuhouser ML, Thompson IM, Lucia MS, Kristal AR. Associations of obesity with prostate cancer risk differ between u.s. African-american and non-Hispanic white men: results from the selenium and vitamin e cancer prevention trial. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 24: 765. PMID 25834168 DOI: 10.1158/1055-9965.Epi-15-0117 |
0.438 |
|
| 2015 |
Ankerst DP, Xia J, Thompson IM, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW. Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. European Urology. 68: 1083-8. PMID 25819722 DOI: 10.1016/J.Eururo.2015.03.023 |
0.424 |
|
| 2015 |
Etzioni R, Gulati R, Lin DW. Measures of survival benefit in cancer drug development and their limitations. Urologic Oncology. 33: 122-7. PMID 25813143 DOI: 10.1016/J.Urolonc.2014.11.002 |
0.306 |
|
| 2015 |
Birnbaum JK, Feng Z, Gulati R, Fan J, Lotan Y, Wei JT, Etzioni R. Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 24: 677-82. PMID 25613117 DOI: 10.1158/1055-9965.Epi-14-1224 |
0.725 |
|
| 2015 |
Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SR. The diffusion of docetaxel in patients with metastatic prostate cancer. Journal of the National Cancer Institute. 107. PMID 25540245 DOI: 10.1093/Jnci/Dju412 |
0.341 |
|
| 2015 |
Ramsey SD, Henry NL, Gralow JR, Mirick DK, Barlow W, Etzioni R, Mummy D, Thariani R, Veenstra DL. Tumor marker usage and medical care costs among older early-stage breast cancer survivors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 149-55. PMID 25332254 DOI: 10.1200/Jco.2014.55.5409 |
0.359 |
|
| 2015 |
Weiner AB, Patel SG, Etzioni R, Eggener SE. National trends in the management of low and intermediate risk prostate cancer in the United States. The Journal of Urology. 193: 95-102. PMID 25106900 DOI: 10.1016/J.Juro.2014.07.111 |
0.475 |
|
| 2015 |
Birnbaum J, Gadi VK, Markowitz E, Etzioni RD. Projecting the impact of treatment advances on the mortality results of mammography screening trials. Journal of Clinical Oncology. 33: e12626-e12626. DOI: 10.1200/Jco.2015.33.15_Suppl.E12626 |
0.579 |
|
| 2015 |
Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni RD. Improving the value of PSA prostate cancer screening with “smarter” strategies and increased use of active surveillance. Journal of Clinical Oncology. 33: 6616-6616. DOI: 10.1200/jco.2015.33.15_suppl.6616 |
0.447 |
|
| 2015 |
Weiner AB, Patel SG, Etzioni R, Eggener SE. National Trends in the Management of Low and Intermediate Risk Prostate Cancer in the United States Journal of Urology. DOI: 10.1016/j.juro.2014.07.111 |
0.357 |
|
| 2014 |
Habbema JD, Wilt TJ, Etzioni R, Nelson HD, Schechter CB, Lawrence WF, Melnikow J, Kuntz KM, Owens DK, Feuer EJ. Models in the development of clinical practice guidelines. Annals of Internal Medicine. 161: 812-8. PMID 25437409 DOI: 10.7326/M14-0845 |
0.339 |
|
| 2014 |
Etzioni R, Xia J, Hubbard R, Weiss NS, Gulati R. A reality check for overdiagnosis estimates associated with breast cancer screening. Journal of the National Cancer Institute. 106. PMID 25362701 DOI: 10.1093/Jnci/Dju315 |
0.402 |
|
| 2014 |
Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5302-10. PMID 25320374 DOI: 10.1158/1078-0432.Ccr-13-3366 |
0.376 |
|
| 2014 |
Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, et al. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1211-9; quiz 1219. PMID 25190691 |
0.457 |
|
| 2014 |
Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR. Expected population impacts of discontinued prostate-specific antigen screening. Cancer. 120: 3519-26. PMID 25065910 DOI: 10.1002/Cncr.28932 |
0.529 |
|
| 2014 |
Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, Kuntz KM, Feuer EJ, Etzioni R, de Koning HJ, et al. Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Annals of Internal Medicine. 161: 104-12. PMID 25023249 DOI: 10.7326/M13-2867 |
0.484 |
|
| 2014 |
Etzioni RD, Thompson IM. What do the screening trials really tell us and where do we go from here? The Urologic Clinics of North America. 41: 223-8. PMID 24725484 DOI: 10.1016/j.ucl.2014.01.002 |
0.389 |
|
| 2014 |
Etzioni R, Gulati R. RE: A model too far. Journal of the National Cancer Institute. 106: dju058. PMID 24659791 DOI: 10.1093/Jnci/Dju058 |
0.546 |
|
| 2014 |
Weiner AB, Etzioni R, Eggener SE. Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance. European Urology. 66: 611-2. PMID 24630416 DOI: 10.1016/J.Eururo.2014.02.051 |
0.494 |
|
| 2014 |
Unger JM, Barlow WE, Martin DP, Ramsey SD, Leblanc M, Etzioni R, Hershman DL. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. Journal of the National Cancer Institute. 106: dju002. PMID 24627276 DOI: 10.1093/Jnci/Dju002 |
0.358 |
|
| 2014 |
Etzioni R. Impact of prostate-specific antigen screening: building confidence. European Urology. 66: 404-5. PMID 24576500 DOI: 10.1016/J.Eururo.2014.02.005 |
0.484 |
|
| 2014 |
Pataky R, Gulati R, Etzioni R, Black P, Chi KN, Coldman AJ, Pickles T, Tyldesley S, Peacock S. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. International Journal of Cancer. Journal International Du Cancer. 135: 939-47. PMID 24443367 DOI: 10.1002/Ijc.28732 |
0.517 |
|
| 2014 |
Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. European Urology. 65: 1046-55. PMID 24439788 DOI: 10.1016/J.Eururo.2013.12.062 |
0.565 |
|
| 2014 |
Gulati R, Inoue LY, Gore JL, Katcher J, Etzioni R. Individualized estimates of overdiagnosis in screen-detected prostate cancer. Journal of the National Cancer Institute. 106: djt367. PMID 24399850 DOI: 10.1093/Jnci/Djt367 |
0.562 |
|
| 2014 |
Inoue LY, Trock BJ, Partin AW, Carter HB, Etzioni R. Modeling grade progression in an active surveillance study. Statistics in Medicine. 33: 930-9. PMID 24123208 DOI: 10.1002/Sim.6003 |
0.451 |
|
| 2014 |
Weiner A, Etzioni R, Eggener S. MP78-11 ONGOING GLEASON GRADE MIGRATION IN LOCALIZED PROSTATE CANCER AND IMPLICATIONS FOR USE OF ACTIVE SURVEILLANCE (2004-2010) Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2494 |
0.497 |
|
| 2014 |
Weiner A, Etzioni R, Eggener S. PD34-10 TRENDS IN MANAGEMENT OF LOW-RISK PROSTATE CANCER IN THE UNITED STATES: A POPULATION-BASED ANALYSIS Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2435 |
0.424 |
|
| 2013 |
Etzioni R, Durand-Zaleski I, Lansdorp-Vogelaar I. Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality. Journal of the National Cancer Institute. Monographs. 2013: 117-23. PMID 23962515 DOI: 10.1093/Jncimonographs/Lgt010 |
0.549 |
|
| 2013 |
Gold LS, Buist DS, Loggers ET, Etzioni R, Kessler L, Ramsey SD, Sullivan SD. Advanced diagnostic breast cancer imaging: variation and patterns of care in Washington state. Journal of Oncology Practice / American Society of Clinical Oncology. 9: e194-202. PMID 23943885 DOI: 10.1200/Jop.2012.000796 |
0.322 |
|
| 2013 |
Schenk JM, Hunter-Merrill R, Zheng Y, Etzioni R, Gulati R, Tangen C, Thompson IM, Kristal AR. Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? American Journal of Epidemiology. 178: 741-51. PMID 23813705 DOI: 10.1093/Aje/Kwt044 |
0.463 |
|
| 2013 |
Etzioni R, Gulati R, Mallinger L, Mandelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Annals of Internal Medicine. 158: 831-8. PMID 23732716 DOI: 10.7326/0003-4819-158-11-201306040-00008 |
0.389 |
|
| 2013 |
Gulati R, Etzioni R. Alternative prostate cancer screening strategies--in response. Annals of Internal Medicine. 158: 778-9. PMID 23689774 DOI: 10.7326/0003-4819-158-10-201305210-00020 |
0.548 |
|
| 2013 |
Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL. Early detection of prostate cancer: AUA Guideline. The Journal of Urology. 190: 419-26. PMID 23659877 DOI: 10.1016/J.Juro.2013.04.119 |
0.534 |
|
| 2013 |
Etzioni R, Gulati R. Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence. Medical Care. 51: 304-6. PMID 23481032 DOI: 10.1097/Mlr.0B013E31828A7E1A |
0.379 |
|
| 2013 |
Ayala G, Frolov A, Ittman M, Mohammed S, LeBlanc M, Falcon S, Rowley D, Etzioni R. Biological correlates of biochemical recurrence free survival using multiple markers in a large tissue microarray cohort. Annals of Clinical and Laboratory Science. 43: 11-21. PMID 23462601 |
0.308 |
|
| 2013 |
Xia J, Gulati R, Au M, Gore JL, Lin DW, Etzioni R. Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial. Journal of the National Cancer Institute. 105: 546-50. PMID 23411592 DOI: 10.1093/Jnci/Djt017 |
0.588 |
|
| 2013 |
Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Annals of Internal Medicine. 158: 145-53. PMID 23381039 DOI: 10.7326/0003-4819-158-3-201302050-00003 |
0.582 |
|
| 2013 |
Wender R, Fontham ET, Barrera E, Colditz GA, Church TR, Ettinger DS, Etzioni R, Flowers CR, Gazelle GS, Kelsey DK, LaMonte SJ, Michaelson JS, Oeffinger KC, Shih YC, Sullivan DC, et al. American Cancer Society lung cancer screening guidelines. Ca: a Cancer Journal For Clinicians. 63: 107-17. PMID 23315954 DOI: 10.3322/Caac.21172 |
0.413 |
|
| 2013 |
Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Medical Care. 51: 295-300. PMID 23269114 DOI: 10.1097/Mlr.0B013E31827Da979 |
0.541 |
|
| 2013 |
Etzioni RD. Review of evidence concerning PSA screening for prostate cancer has limitations as basis for policy development. Evidence-Based Medicine. 18: 75-6. PMID 22773765 DOI: 10.1136/eb-2012-100803 |
0.44 |
|
| 2013 |
Inoue LYT, Gulati R, Yu C, Kattan MW, Etzioni R. Deriving benefit of early detection from biomarker-based prognostic models Biostatistics. 14: 15-27. PMID 22730510 DOI: 10.1093/Biostatistics/Kxs018 |
0.381 |
|
| 2012 |
Yu EY, Kuo KF, Hunter-Merrill R, Gulati R, Hall SP, Gambol TE, Etzioni RD, Higano CS. Relationship of time to testosterone (T) and PSA rises during the first "off treatment" interval (1OFF) of intermittent androgen deprivation (IAD) with time to castration resistance (CRPC) and prostate cancer mortality (PCM) in men with biochemical relapse (BR). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 99. PMID 28143340 DOI: 10.1200/jco.2012.30.5_suppl.99 |
0.309 |
|
| 2012 |
Yu EY, Kuo KF, Hunter-Merrill R, Gulati R, Hall SP, Gambol TE, Etzioni RD, Higano CS. Relationship of time to testosterone (T) and PSA rises during the first "off treatment" interval (1OFF) of intermittent androgen deprivation (IAD) with time to castration resistance (CRPC) and prostate cancer mortality (PCM) in men with biochemical relapse (BR). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 99. PMID 27968281 DOI: 10.1200/jco.2012.30.5_suppl.99 |
0.309 |
|
| 2012 |
Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5471-8. PMID 23008476 DOI: 10.1158/1078-0432.Ccr-12-1502 |
0.508 |
|
| 2012 |
Mandelblatt J, Schechter C, Levy D, Zauber A, Chang Y, Etzioni R. Building better models: if we build them, will policy makers use them? Toward integrating modeling into health care decisions. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 32: 656-9. PMID 22990079 DOI: 10.1177/0272989X12458978 |
0.353 |
|
| 2012 |
Etzioni R, Mucci L, Chen S, Johansson JE, Fall K, Adami HO. Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6742-7. PMID 22927485 DOI: 10.1158/1078-0432.Ccr-12-1537 |
0.531 |
|
| 2012 |
Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 118: 5955-63. PMID 22605665 DOI: 10.1002/Cncr.27594 |
0.515 |
|
| 2012 |
Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EA, Katcher J, de Koning HJ, Etzioni R. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes & Control : Ccc. 23: 827-35. PMID 22488488 DOI: 10.1007/S10552-012-9951-8 |
0.462 |
|
| 2012 |
Zeliadt SB, Buist DS, Reid RJ, Grossman DC, Ma J, Etzioni R. Biopsy follow-up of prostate-specific antigen tests. American Journal of Preventive Medicine. 42: 37-43. PMID 22176844 DOI: 10.1016/J.Amepre.2011.08.024 |
0.498 |
|
| 2012 |
Etzioni R. Abstract FO01-01: Estimating how many prostate cancers are overdiagnosed: Overcoming challenges and avoiding mistakes Cancer Prevention Research. 5: FO01-01-FO01-01. DOI: 10.1158/1940-6207.Prev-12-Fo01-01 |
0.577 |
|
| 2011 |
Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. Journal of Clinical Epidemiology. 64: 1412-7. PMID 22032753 DOI: 10.1016/J.Jclinepi.2011.06.011 |
0.535 |
|
| 2011 |
Gulati R, Wever EM, Tsodikov A, Penson DF, Inoue LY, Katcher J, Lee SY, Heijnsdijk EA, Draisma G, de Koning HJ, Etzioni R. What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 740-50. PMID 21546365 DOI: 10.1158/1055-9965.Epi-10-0718 |
0.512 |
|
| 2011 |
Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. Journal of the National Cancer Institute. 103: 520-3. PMID 21357307 DOI: 10.1093/Jnci/Djr007 |
0.548 |
|
| 2011 |
Ramsey SD, Etzioni R. Case-control studies of cancer surveillance procedures. Journal of Clinical Epidemiology. 64: 44. PMID 21130351 DOI: 10.1016/J.Jclinepi.2010.07.011 |
0.361 |
|
| 2011 |
Zeliadt S, Buist D, Reid R, Grossman D, Chen S, Etzioni R. PS2-43: Prostate-Specific Antigen Tests in Clinical Practice over the Past Decade: Is the Threshold for Recommending Biopsy Dropping? Clinical Medicine & Research. 9: 146-147. DOI: 10.3121/Cmr.2011.1020.Ps2-43 |
0.453 |
|
| 2011 |
Morrissey C, Coleman I, Chen S, Coleman R, Gulati R, Lakely B, Brown LG, Kinnunen M, Corey E, Etzioni R, Lange PH, Nelson PS, Vessella RL. Abstract 5242: Obtaining a transcriptomic profile of a single prostate cancer cell Cancer Research. 71: 5242-5242. DOI: 10.1158/1538-7445.Am2011-5242 |
0.328 |
|
| 2011 |
Zeliadt S, Etzioni R, Saigal C, Lai J, Gore J. 311 Costs And Sequela Following Psa Testing Among Healthy Insured Men In The U.S. The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2630 |
0.317 |
|
| 2010 |
Fedewa SA, Etzioni R, Flanders WD, Jemal A, Ward EM. Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 2437-44. PMID 20705937 DOI: 10.1158/1055-9965.Epi-10-0299 |
0.512 |
|
| 2010 |
Zeliadt SB, Hoffman RM, Etzioni R, Ginger VA, Lin DW. What happens after an elevated PSA test: the experience of 13,591 veterans. Journal of General Internal Medicine. 25: 1205-10. PMID 20697965 DOI: 10.1007/S11606-010-1468-9 |
0.486 |
|
| 2010 |
Gulati R, Inoue L, Katcher J, Hazelton W, Etzioni R. Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics (Oxford, England). 11: 707-19. PMID 20530126 DOI: 10.1093/Biostatistics/Kxq036 |
0.524 |
|
| 2010 |
Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni RD, Higano CS. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2668-73. PMID 20421544 DOI: 10.1200/Jco.2009.25.1330 |
0.38 |
|
| 2010 |
Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA. American Cancer Society guideline for the early detection of prostate cancer: update 2010. Ca: a Cancer Journal For Clinicians. 60: 70-98. PMID 20200110 DOI: 10.3322/caac.20066 |
0.472 |
|
| 2010 |
Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, Catalona WJ, Cookson MS, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Howe RJ, Lange PH, Lilja H, et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. Journal of the National Comprehensive Cancer Network : Jnccn. 8: 240-62. PMID 20141680 DOI: 10.6004/Jnccn.2010.0016 |
0.44 |
|
| 2010 |
Zeliadt SB, Hoffman RM, Gore JL, Etzioni R, Kessler LG, Lin DW. 1988 DECLINES IN PSA UTILIZATION AFTER THE 2008 PSA SCREENING GUIDELINES Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1999 |
0.435 |
|
| 2009 |
Shaw PA, Pepe MS, Alonzo TA, Etzioni R. Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test. Statistics in Biopharmaceutical Research. 1: 18-25. PMID 20054437 DOI: 10.1198/Sbr.2009.0002 |
0.433 |
|
| 2009 |
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. Journal of the National Cancer Institute. 101: 374-83. PMID 19276453 DOI: 10.1093/Jnci/Djp001 |
0.547 |
|
| 2009 |
Fesinmeyer MD, Gulati R, Zeliadt S, Weiss N, Kristal AR, Etzioni R. Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 808-15. PMID 19258479 DOI: 10.1158/1055-9965.Epi-08-0784 |
0.496 |
|
| 2009 |
Etzioni R, Kessler L, Di Tommaso D. Using Public Health Data to Evaluate Screening Programs: Application to Prostate Cancer Monitoring the Health of Populations : Statistical Principles and Methods For Public Health Surveillance. DOI: 10.1093/acprof:oso/9780195146493.003.0006 |
0.493 |
|
| 2009 |
Zeliadt SB, Ginger VAT, Etzioni R, Lin DW. FOLLOW UP AND BIOPSY PATTERNS AFTER ELEVATED PROSTATE SPECIFIC ANTIGEN (PSA) TESTS Journal of Urology. 181: 751-752. DOI: 10.1016/S0022-5347(09)62095-4 |
0.431 |
|
| 2008 |
Gulati R, Yu EY, Telesca D, Jiang P, Montgomery RB, Tam S, Russell KJ, Nelson PS, Etzioni RB, Higano CS. Testosterone kinetics in the first cycle of intermittent androgen deprivation (IAD) for men with localized or biochemical relapse (BR) of prostate cancer (PC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5134. PMID 27948211 DOI: 10.1200/Jco.2008.26.15_Suppl.5134 |
0.313 |
|
| 2008 |
Inoue LY, Etzioni R, Morrell C, Müller P. Modeling Disease Progression with Longitudinal Markers. Journal of the American Statistical Association. 103: 259-270. PMID 24453387 DOI: 10.1198/016214507000000356 |
0.382 |
|
| 2008 |
Thompson IM, Ankerst DP, Etzioni R, Wang T. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. The Journal of Urology. 180: 1219-22. PMID 18707707 DOI: 10.1016/J.Juro.2008.07.089 |
0.494 |
|
| 2008 |
Etzioni R, Feuer E. Studies of prostate-cancer mortality: caution advised. The Lancet. Oncology. 9: 407-9. PMID 18452850 DOI: 10.1016/S1470-2045(08)70112-8 |
0.517 |
|
| 2008 |
Etzioni R. Statistical issues in the evaluation of screening and early detection modalities. Urologic Oncology. 26: 308-15. PMID 18452826 DOI: 10.1016/J.Urolonc.2006.11.008 |
0.488 |
|
| 2008 |
Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 28: 323-31. PMID 18319508 DOI: 10.1177/0272989X07312719 |
0.548 |
|
| 2008 |
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF, Feuer E. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes & Control : Ccc. 19: 175-81. PMID 18027095 DOI: 10.1007/S10552-007-9083-8 |
0.577 |
|
| 2008 |
Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics. 64: 10-9. PMID 17501937 DOI: 10.1111/J.1541-0420.2007.00825.X |
0.536 |
|
| 2007 |
Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. Journal of the National Cancer Institute. 99: 1510-5. PMID 17925534 DOI: 10.1093/jnci/djm171 |
0.451 |
|
| 2007 |
Kawachi MH, Bahnson RR, Barry M, Carroll PR, Carter HB, Catalona WJ, Epstein JI, Etzioni RB, Hemstreet GP, Howe RJ, Kopin JD, Lange PH, Lilja H, Mohler J, Moul J, et al. Prostate cancer early detection. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 5: 714-36. PMID 17692177 |
0.403 |
|
| 2007 |
Ramsey SD, Howlader N, Etzioni R, Brown ML, Warren JL, Newcomb P. Surveillance endoscopy does not improve survival for patients with local and regional stage colorectal cancer. Cancer. 109: 2222-8. PMID 17410533 DOI: 10.1002/Cncr.22673 |
0.42 |
|
| 2007 |
Etzioni RD, Ankerst DP, Thompson IM. Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. Journal of the National Cancer Institute. 99: 489-90; author reply. PMID 17374841 DOI: 10.1093/jnci/djk100 |
0.395 |
|
| 2007 |
Mariotto AB, Etzioni R, Krapcho M, Feuer EJ. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer. 109: 1877-86. PMID 17372918 DOI: 10.1002/Cncr.22607 |
0.378 |
|
| 2007 |
Zeliadt SB, Etzioni R, Ramsey SD, Penson DF, Potosky AL. Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Medical Care. 45: 154-9. PMID 17224778 DOI: 10.1097/01.Mlr.0000241044.09778.3F |
0.512 |
|
| 2007 |
Telesca D, Higano CS, Yu EY, Montgomery RB, Tam SL, Russell KJ, Nelson PS, Etzioni RB. Duration of the first off treatment period is associated with time to androgen independence (AI) and survival in men with localized or biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation (IAD) Journal of Clinical Oncology. 25: 5146-5146. DOI: 10.1200/Jco.2007.25.18_Suppl.5146 |
0.342 |
|
| 2006 |
Zeliadt SB, Potosky AL, Penson DF, Etzioni R. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 66: 395-402. PMID 16904843 DOI: 10.1016/J.Ijrobp.2006.04.048 |
0.405 |
|
| 2006 |
Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 106: 320-8. PMID 16342294 DOI: 10.1002/Cncr.21603 |
0.431 |
|
| 2006 |
Pinsky P, Etzioni R, Howlader N, Goodman P, Thompson IM. Modeling the effect of a preventive intervention on the natural history of cancer: Application to the Prostate Cancer Prevention Trial International Journal of Biostatistics. 2. DOI: 10.2202/1557-4679.1036 |
0.564 |
|
| 2005 |
Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. The Journal of Urology. 174: 877-81. PMID 16093979 DOI: 10.1097/01.ju.0000169255.64518.fb |
0.413 |
|
| 2005 |
Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. The American Journal of Medicine. 118: 850-7. PMID 16084177 DOI: 10.1016/J.Amjmed.2005.03.001 |
0.441 |
|
| 2005 |
Zeliadt SB, Etzioni R, Kristal AR. Estimated impact of the prostate cancer prevention trial on population mortality. Cancer. 104: 1556-7; author reply. PMID 16015625 DOI: 10.1002/Cncr.21344 |
0.507 |
|
| 2005 |
Etzioni R, Hawley S, Billheimer D, True LD, Knudsen B. Analyzing patterns of staining in immunohistochemical studies: application to a study of prostate cancer recurrence. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 1040-6. PMID 15894650 DOI: 10.1158/1055-9965.Epi-04-0584 |
0.433 |
|
| 2005 |
Friedrichsen DM, Hawley S, Shu J, Humphrey M, Sabacan L, Iwasaki L, Etzioni R, Ostrander EA, Stanford JL. IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. The Prostate. 65: 44-51. PMID 15800934 DOI: 10.1002/Pros.20259 |
0.384 |
|
| 2005 |
Moore S, Knudsen B, True LD, Hawley S, Etzioni R, Wade C, Gifford D, Coleman I, Nelson PS. Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. International Journal of Cancer. Journal International Du Cancer. 114: 563-71. PMID 15609334 DOI: 10.1002/Ijc.20773 |
0.441 |
|
| 2004 |
Zeliadt SB, Etzioni R, Penson DF, Ramsey SD. Cost-effectiveness and lifetime implications of using finasteride to reduce prostate cancer incidence and mortality. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1028. PMID 28014704 DOI: 10.1200/Jco.2004.22.14_Suppl.1028 |
0.397 |
|
| 2004 |
Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 64: 1171-6. PMID 15596192 DOI: 10.1016/J.Urology.2004.07.037 |
0.509 |
|
| 2004 |
Feuer EJ, Etzioni R, Cronin KA, Mariotto A. The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Statistical Methods in Medical Research. 13: 421-42. PMID 15587432 DOI: 10.1191/0962280204Sm376Ra |
0.488 |
|
| 2004 |
Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, Weiss NS, Feuer EJ. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. American Journal of Epidemiology. 160: 1059-69. PMID 15561985 DOI: 10.1093/Aje/Kwh336 |
0.553 |
|
| 2004 |
Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Metastases of prostate cancer express estrogen receptor-beta. Urology. 64: 814-20. PMID 15491740 DOI: 10.1016/j.urology.2004.05.036 |
0.32 |
|
| 2004 |
Etzioni R, Falcon S, Gann PH, Kooperberg CL, Penson DF, Stampfer MJ. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection? Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 13: 1640-5. PMID 15466981 |
0.39 |
|
| 2004 |
Etzioni R, Thomas DB. Modelling the effect of screening for cervical cancer on the population. Lancet (London, England). 364: 224-6. PMID 15262081 DOI: 10.1016/S0140-6736(04)16687-7 |
0.42 |
|
| 2004 |
Weiss NS, Dhillon PK, Etzioni R. Case-control studies of the efficacy of cancer screening: overcoming bias from nonrandom patterns of screening. Epidemiology (Cambridge, Mass.). 15: 409-13. PMID 15232400 DOI: 10.1097/01.Ede.0000129518.99816.E1 |
0.419 |
|
| 2004 |
Inoue LY, Etzioni R, Slate EH, Morrell C, Penson DF. Combining longitudinal studies of PSA. Biostatistics (Oxford, England). 5: 483-500. PMID 15208207 DOI: 10.1093/Biostatistics/Kxh003 |
0.491 |
|
| 2004 |
Ramsey SD, Mandelson MT, Etzioni R, Harrison R, Smith R, Taplin S. Can administrative data identify incident cases of colorectal cancer? A comparison of two health plans Health Services and Outcomes Research Methodology. 5: 27-37. DOI: 10.1007/S10742-005-5562-0 |
0.393 |
|
| 2003 |
Ramsey SD, Mandelson MT, Berry K, Etzioni R, Harrison R. Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer. Gastroenterology. 125: 1645-50. PMID 14724816 DOI: 10.1053/J.Gastro.2003.09.032 |
0.452 |
|
| 2003 |
Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R, Barnett MJ, Goodman GE. Endogenous Sex Hormones and Prostate Cancer Risk: A Case-Control Study Nested within the Carotene and Retinol Efficacy Trial Cancer Epidemiology Biomarkers and Prevention. 12: 1410-1416. PMID 14693730 |
0.303 |
|
| 2003 |
Etzioni R, Kooperberg C, Pepe M, Smith R, Gann PH. Combining biomarkers to detect disease with application to prostate cancer Biostatistics (Oxford, England). 4: 523-538. PMID 14557109 DOI: 10.1093/Biostatistics/4.4.523 |
0.529 |
|
| 2003 |
Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis Cancer. 98: 496-503. PMID 12879465 DOI: 10.1002/Cncr.11492 |
0.363 |
|
| 2003 |
Lamharzi N, Johnson MM, Goodman G, Etzioni R, Weiss NS, Dightman DA, Barnett M, DiTommaso D, Chen C. Polymorphic markers in the 5α-reductase type II gene and the incidence of prostate cancer International Journal of Cancer. 105: 480-483. PMID 12712437 DOI: 10.1002/Ijc.11126 |
0.433 |
|
| 2003 |
Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L. The case for early detection. Nature Reviews. Cancer. 3: 243-52. PMID 12671663 DOI: 10.1038/Nrc1041 |
0.466 |
|
| 2002 |
Weiss NS, Etzioni R. Estimating the influence of rescreening interval on the benefits associated with cancer screening: Approaches and limitations Epidemiology. 13: 713-717. PMID 12410014 DOI: 10.1097/00001648-200211000-00017 |
0.473 |
|
| 2002 |
Chen C, Lamharzi N, Weiss NS, Etzioni R, Dightman DA, Barnett M, DiTommaso D, Goodman G. Androgen receptor polymorphisms and the incidence of prostate cancer Cancer Epidemiology Biomarkers and Prevention. 11: 1033-1040. PMID 12376504 |
0.35 |
|
| 2002 |
Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data Medical Care. 40. PMID 12187175 DOI: 10.1097/00005650-200208001-00014 |
0.361 |
|
| 2002 |
Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. Journal of the National Cancer Institute. 94: 981-90. PMID 12096083 DOI: 10.1093/Jnci/94.13.981 |
0.554 |
|
| 2002 |
Etzioni R, Riley GF, Ramsey SD, Brown M. Measuring costs: administrative claims data, clinical trials, and beyond Medical Care. 40. PMID 12064760 DOI: 10.1097/00005650-200206001-00010 |
0.336 |
|
| 2002 |
Ramsey SD, Berry K, Etzioni R. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. The American Journal of Gastroenterology. 97: 440-5. PMID 11866285 DOI: 10.1111/j.1572-0241.2002.05483.x |
0.385 |
|
| 2002 |
Etzioni R, Berry KM, Legler JM, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. Urology. 59: 251-5. PMID 11834397 DOI: 10.1016/S0090-4295(01)01516-3 |
0.474 |
|
| 2002 |
Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N, Moeslein G. Microsatellite screening for hereditary nonpolyposis colorectal cancer is cost-effective Evidence-Based Healthcare. 6: 160. DOI: 10.1054/ebhc.2002.0561 |
0.311 |
|
| 2001 |
Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Annals of Internal Medicine. 135: 577-88. PMID 11601929 DOI: 10.7326/0003-4819-135-8_Part_1-200110160-00008 |
0.459 |
|
| 2001 |
Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. Journal of the National Cancer Institute. 93: 1054-61. PMID 11459866 DOI: 10.1093/Jnci/93.14.1054 |
0.365 |
|
| 2001 |
Ellis WJ, Etzioni R, Vessella RL, Hu C, Goodman GE. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer Journal of Urology. 166: 93-98. PMID 11435831 DOI: 10.1016/S0022-5347(05)66084-3 |
0.532 |
|
| 2001 |
Etzioni R, Ramsey SD, Berry K, Brown M. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. Health Economics. 10: 245-56. PMID 11288190 DOI: 10.1002/Hec.580 |
0.338 |
|
| 2000 |
Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, Urban N. Quality of life in survivors of colorectal carcinoma Cancer. 88: 1294-1303. PMID 10717609 DOI: 10.1002/(Sici)1097-0142(20000315)88:6<1294::Aid-Cncr4>3.0.Co;2-M |
0.363 |
|
| 1999 |
Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care: Application to medicare enrollees diagnosed with colorectal cancer Medical Care. 37: 1249-1259. PMID 10599606 DOI: 10.1097/00005650-199912000-00008 |
0.305 |
|
| 1999 |
Etzioni R, Cha R, Cowen ME. Serial prostate specific antigen screening for prostate cancer: A computer model evaluates competing strategies Journal of Urology. 162: 741-748. PMID 10458357 DOI: 10.1097/00005392-199909010-00032 |
0.41 |
|
| 1999 |
Etzioni R, Pepe M, Longton G, Hu C, Goodman G. Incorporating the time dimension in receiver operating characteristic curves: A case study of prostate cancer Medical Decision Making. 19: 242-251. PMID 10424831 DOI: 10.1177/0272989X9901900303 |
0.52 |
|
| 1999 |
Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. Journal of the National Cancer Institute. 91: 1033-9. PMID 10379966 DOI: 10.1093/Jnci/91.12.1033 |
0.534 |
|
| 1999 |
Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptomatic Incidence and Duration of Prostate Cancer The Journal of Urology. 162: 265-266. DOI: 10.1097/00005392-199907000-00083 |
0.541 |
|
| 1999 |
Etzioni R, Cha R, Cowen ME. Serial Psa Screening For Prostate Cancer: A Computer Model Evaluates Competing Strategies The Journal of Urology. 291. DOI: 10.1097/00005392-199904020-00167 |
0.554 |
|
| 1999 |
Goodman GE, Ellis WJ, Etzioni R, Vessella RL. Serial Prostate Specific Antigen (Psa) And Free/Total Psa (F/T Psa) Ratio In The Diagnosis Of Prostate Cancer The Journal of Urology. 95. DOI: 10.1097/00005392-199904010-00382 |
0.478 |
|
| 1998 |
Cronin KA, Legler JM, Etzioni RD. Assessing uncertainty in microsimulation modelling with application to cancer screening interventions. Statistics in Medicine. 17: 2509-23. PMID 9819842 DOI: 10.1002/(SICI)1097-0258(19981115)17:21<2509::AID-SIM949>3.0.CO;2-V |
0.31 |
|
| 1998 |
Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptornatic incidence and duration of prostate cancer American Journal of Epidemiology. 148: 775-785. PMID 9786232 DOI: 10.1093/Oxfordjournals.Aje.A009698 |
0.54 |
|
| 1998 |
Etzioni RD, Weiss NS. Analysis of case-control studies of screening: Impact of misspecifying the duration of detectable preclinical pathologic changes American Journal of Epidemiology. 148: 292-297. PMID 9690367 |
0.313 |
|
| 1997 |
Urban N, Drescher C, Etzioni R, Colby C. Use of stochastic stimulation model to identify an efficient protocol for ovarian cancer screening Controlled Clinical Trials. 18: 251-270. PMID 9204225 DOI: 10.1016/S0197-2456(96)00233-4 |
0.4 |
|
| 1997 |
Etzioni R, Shen Y. Estimating asymptomatic duration in cancer: The aids connection Statistics in Medicine. 16: 627-644. PMID 9131752 DOI: 10.1002/(Sici)1097-0258(19970330)16:6<627::Aid-Sim438>3.0.Co;2-7 |
0.455 |
|
| 1996 |
Etzioni R, Shen Y, Petteway JC, Brawer MK. Age-specific prostate-specific antigen: A reassessment Prostate. 29: 70-77. PMID 8950367 DOI: 10.1002/(Sici)1097-0045(1996)7+<70::Aid-Pros10>3.0.Co;2-O |
0.516 |
|
| 1996 |
Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology. 47: 863-9. PMID 8677578 DOI: 10.1016/S0090-4295(96)00061-1 |
0.504 |
|
| 1996 |
Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer Journal of Clinical Epidemiology. 49: 95-103. PMID 8598518 DOI: 10.1016/0895-4356(96)89259-6 |
0.357 |
|
| 1996 |
Etzioni R, Thompson IM. Prostate cancer and computer models: Background, limitations, and potential Urologic Oncology. 2: 57-64. DOI: 10.1016/S1078-1439(96)00047-6 |
0.469 |
|
| 1995 |
Urban N, Taplin SH, Taylor VM, Peacock S, Anderson G, Conrad D, Etzioni R, White E, Montano DE, Mahloch J, Majer K. Community Organization to Promote Breast Cancer Screening among Women Ages 50-75 Preventive Medicine. 24: 477-484. PMID 8524722 DOI: 10.1006/Pmed.1995.1076 |
0.308 |
|
| 1995 |
Self SG, Etzioni R. A likelihood ratio test for cancer screening trials Biometrics. 51: 44-50. PMID 7766795 DOI: 10.2307/2533313 |
0.421 |
|
| 1995 |
Etzioni R, Self SG. On the catch-up time method for analyzing cancer screening trials Biometrics. 51: 31-43. PMID 7766785 DOI: 10.2307/2533312 |
0.396 |
|
| 1995 |
Etzioni RD, Self SG, Connor RJ, Prorok PC. Design and analysis of cancer screening trials Statistical Methods in Medical Research. 4: 3-17. PMID 7613636 DOI: 10.1177/096228029500400102 |
0.307 |
|
| Show low-probability matches. |